Status: Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Participants needed: 70
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Context Therapeutics Inc.Updated: Jun 12, 2026Locations: 9
Eligibility criteria
ECOG 0 or 1 [+3]
Uncontrolled significant active infection or any medical or other condition that... [+3]